The long‐term outcome of patients with polycystic liver disease treated with lanreotide

Chrispijn, Melissa; Nevens, Frederik; Gevers, Tom J.G.; Vanslembrouck, Ragna; Oijen, Martijn G.H. van; Coudyzer, Walter; Hoffmann, Aswin L.; Dekker, Helena M.; Man, Robert A. de; Keimpema, Loes van; Drenth, Joost P.H.

doi:10.1111/j.1365-2036.2011.04923.x

Cited by 92 publications

(59 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[160][161][162][163] Two of these studies have been extended as open-label, uncontrolled studies. 164,165 The results of a fourth study comparing the effects of octreotide plus everolimus with octreotide alone (NCT01157858) have also been published. Additional clinical trials of somatostatin analogs for ADPKD and/ or polycystic liver disease are currently active.…”

Section: Somatostatin Analogs: Clinical Trialsmentioning

confidence: 99%

Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease

Torres

Harris

2014

Journal of the American Society of Nephrology

244

218

View full text Add to dashboard Cite

Polycystic kidney disease (PKD) is a leading cause of ESRD worldwide. In PKD, excessive cell proliferation and fluid secretion, pathogenic interactions of mutated epithelial cells with an abnormal extracellular matrix and alternatively activated interstitial macrophages, and the disruption of mechanisms controlling tubular diameter contribute to cyst formation. Studies with animal models suggest that several diverse pathophysiologic mechanisms, including dysregulation of intracellular calcium levels and cAMP signaling, mediate these cystogenic mechanisms. This article reviews the evidence implicating calcium and cAMP as central players in a network of signaling pathways underlying the pathogenesis of PKD and considers the therapeutic relevance of treatment strategies targeting cAMP signaling.

show abstract

Section: Somatostatin Analogs: Clinical Trialsmentioning

confidence: 99%

Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease

Torres

Harris

2014

Journal of the American Society of Nephrology

244

218

View full text Add to dashboard Cite

show abstract

“…As a result, seven studies were included in the final review (Table 1). 3,[18][19][20][21][22][23] Five of these (three RCTs 3,18,19 and two further subsequent publications) 20,21 investigated the role somatostatin analogues ( Table 2). The remaining two studies (one RCT 22 and one case series) 23 investigated the role of mTOR inhibitors ( Table 3).…”

Section: Resultsmentioning

confidence: 99%

Medical therapy for polycystic liver disease

Khan

Dennison

Garcea

2016

annals

View full text Add to dashboard Cite

Introduction Somatostatin analogues and rapamycin inhibitors are two classes of drugs available for the management of polycystic liver disease but their overall impact is not clearly established. This article systematically reviews the literature on the medical management of polycystic liver disease. The outcomes assessed include reduction in liver volume and the impact on quality of life. Methods The English language literature published between 1966 and August 2014 was reviewed from a MEDLINE®, PubMed, Embase™ and Cochrane Library search. Search terms included ‘polycystic’, ‘liver’, ‘sirolimus’, ‘everolimus’, ‘PCLD’, ‘somatostatin’, ‘octreotide’, ‘lanreotide’ and ‘rapamycin’. Both randomised trials and controlled studies were included. References of the articles retrieved were also searched to identify any further eligible publications. The studies included were appraised using the Jadad score. Results Seven studies were included in the final review. Five studies, of which three were randomised trials, investigated the role of somatostatin analogues and the results showed a mean reduction in liver volume ranging from 2.9% at six months to 4.95 ±6.77% at one year. Only one randomised study examined the influence of rapamycin inhibitors. This trial compared dual therapy with everolimus and octreotide versus octreotide monotherapy. Liver volume reduced by 3.5% and 3.8% in the control and intervention groups respectively but no statistical difference was found between the two groups (p=0.73). Two randomised trials investigating somatostatin analogues assessed quality of life using SF-36®. Only one subdomain score improved in one of the trials while two subdomain scores improved in the other with somatostatin analogue therapy. Conclusions Somatostatin analogues significantly reduce liver volumes after six months of therapy but have only a modest improvement on quality of life. Rapamycin inhibitors do not confer any additional advantage.

show abstract

“…We and others showed that somatostatinanalogues (SA), i.e. lanreotide and octreotide, decrease liver volume [7][8][9][10]. In addition, we recently demonstrated that a reduction of ≥120mL in liver volume after 6 months has a high positive predictive value of improving complaints, a reduction which lies above the 95% upper limit of the confidence intervals of the differences in LV assessed by two software methods measuring the same LV [11].…”

Section: Introductionmentioning

confidence: 97%

Development and validation of a polycystic liver disease complaint-specific assessment (POLCA)

Temmerman

Dobbels

et al. 2014

Journal of Hepatology

View full text Add to dashboard Cite

The long‐term outcome of patients with polycystic liver disease treated with lanreotide

Abstract: SUMMARY BackgroundPolycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease. Somatostatin analogues, such as lanreotide, reduce polycystic liver volume.

Cited by 92 publications

References 24 publications

Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease

Strategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease

Medical therapy for polycystic liver disease

Development and validation of a polycystic liver disease complaint-specific assessment (POLCA)

Contact Info

Product

Resources

About